Home/Filings/4/0001209191-23-016397
4//SEC Filing

Ramelmeier Rolf Andrew 4

Accession 0001209191-23-016397

CIK 0001001233other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 5:09 PM ET

Size

11.2 KB

Accession

0001209191-23-016397

Insider Transaction Report

Form 4
Period: 2023-02-24
Ramelmeier Rolf Andrew
EVP, Technical Operations
Transactions
  • Award

    Common Stock

    2023-02-24+45,000188,835 total
  • Tax Payment

    Common Stock

    2023-02-25$2.66/sh15,618$41,544173,217 total
  • Award

    Stock Option (Right to Buy)

    2023-02-24+210,000210,000 total
    Exercise: $2.66Exp: 2033-02-23Common Stock (210,000 underlying)
Footnotes (5)
  • [F1]Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F2]Includes 690 shares acquired on May 31, 2022 and 716 shares acquired on November 30, 2022 under the Issuer's 2020 Employee Stock Purchase Plan.
  • [F3]Represents shares underlying the portions of RSU grants that vested on February 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on February 24, 2023 of $2.66/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
  • [F4]Includes: (a) 11,997 shares resulting from the February 25, 2023 final vesting installment of the Reporting Person's February 25, 2020 RSU grant, (b) 8,722 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2021 RSU grant and 13,336 shares subject to such RSU grant that will vest in one final installment on February 25, 2024 and (c) 8,832 shares resulting from the February 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 40,500 shares will vest in 8 successive equal quarterly installments. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
  • [F5]One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Issuer

SANGAMO THERAPEUTICS, INC

CIK 0001001233

Entity typeother

Related Parties

1
  • filerCIK 0001789340

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 5:09 PM ET
Size
11.2 KB